Braveheart Bio Surges 66% on Nasdaq Debut, Fueling Phase 3 Push for Camzyos Rival

Braveheart Bio (BRVE) closed at $29.80 on its first day of Nasdaq trading August 6, a 66% pop from the $18 IPO price that values the cardiac drug developer at roughly $1.9 billion. The company raised $382.5 million by selling 21.25 million shares, upsizing the deal by 27% after pricing above the $15 to $17 range.

The proceeds fund BHB-1893, an oral cardiac myosin inhibitor licensed from China’s Hengrui Pharma for $65 million upfront in 2025. Cardiac myosin inhibitors reduce the excessive contraction of heart muscle that drives hypertrophic cardiomyopathy (HCM), a genetic condition affecting roughly 1 in 500 people where the heart wall thickens and impairs blood flow. Braveheart has allocated $90 million to start a Phase 3 trial in obstructive HCM (oHCM) later this year and another $100 million for a Phase 3 study in non-obstructive HCM (nHCM) in the first half of 2027. The drug is positioned as next-generation: Hengrui’s Phase 2 data showed rapid onset of action with minimal impact on left ventricular ejection fraction, an advantage over first-generation cardiac myosin inhibitors.

The HCM market is expanding rapidly. Bristol Myers Squibb’s Camzyos, the only approved cardiac myosin inhibitor in the US, generated $416 million in Q2 2026 revenue, up 60% year over year. Cytokinetics’ Myqorzo (aficamten) is the second entrant and reported positive Phase 3 data in nHCM in May 2026 — a result that makes Braveheart’s nHCM study a three-way race rather than a two-horse field. There is no FDA-approved treatment for nHCM yet, and the first company to file in that indication could capture a patient population roughly equal in size to the obstructive form.

Braveheart joins a busy August IPO window. It follows Attovia Therapeutics’ $289 million upsized IPO earlier this week, and the strong debut signals that public investors remain eager to fund late-stage cardiometabolic assets in categories where large pharma has already proven commercial demand.

The risk: BHB-1893 has Phase 2 data from Hengrui’s original Chinese program, but the registrational trials have not started. Camzyos will have a multi-year head start, and Myqorzo could expand into nHCM before Braveheart’s trial reads out. Hengrui dependency, both for the molecule and the existing clinical data package, is the other overhang. The $65 million license deal gave Braveheart a clinical-stage asset without the discovery cost, but it also means the company does not control the underlying IP. Investors are betting that $382.5 million and an experienced management team can execute faster than the incumbents can lock down the market.

What It Means for the Trade

The 66% debut pop to a $1.9 billion valuation is the market paying up for two things: a validated class (cardiac myosin inhibition) and a visible commercial demand curve (Camzyos at $416 million in Q2, growing 60%). The discipline the pop demands is remembering what Braveheart actually is: a late-entrant with $382.5 million, a licensed molecule, and zero registrational data in its target market — going up against the only approved incumbent and a second entrant with Phase 3 wins already banked. The China-licensed-asset IPO structure is well-understood now: the market pays for the Phase 3 execution the company hasn’t started. The two-year window between IPO and first registrational readout is where these stories live or die, and the $190 million allocated to the two Phase 3 starts ($90 million oHCM late this year, $100 million nHCM in H1 2027) is runway math, not proof of anything.

The nHCM race is where the valuation gets decided. No FDA-approved therapy exists for non-obstructive HCM, the population is roughly the size of the obstructive form, and there are now three credible contenders: Cytokinetics with positive Phase 3 data in hand from May 2026, Braveheart with a trial not yet started, and BMS’s Camzyos with its own expansion ambitions. In a first-to-label race, the entrant with data already banked holds the advantage — Braveheart’s nHCM trial reads out years after Cytokinetics’ already-positive result, which means Braveheart’s realistic prize in nHCM is second-entrant share, not first-mover economics. The oHCM setting is even tougher: Camzyos is approved and scaling at 60% growth, and Myqorzo is already the second approved agent there. A third drug entering oHCM in 2028-plus competes for switch patients on the strength of Phase 2 data from a Chinese origin trial.

Mechanism and Company Context

The mechanistic pitch is real and worth taking seriously. BHB-1893’s Phase 2 profile — rapid onset with minimal LVEF impact — targets the known weaknesses of first-generation cardiac myosin inhibitors: mavacamten’s slow titration requirements and the ejection-fraction monitoring burden that comes with excessive myosin inhibition. A next-generation molecule with cleaner cardiac-index separation would be a genuine differentiator, and myosin-inhibitor class mechanics (reducing the excessive actin-myosin cross-bridge formation that drives HCM’s hypercontractility) are validated biology at this point. But the Hengrui dependency cuts through everything: the Phase 2 data package was generated in China under different trial conditions, and the FDA’s multiregional evidence bar means the registrational trials are essentially first-in-U.S. studies regardless of what the Chinese data showed. The license structure also means the underlying IP and the originator’s own commercial ambitions in other territories are permanent deal-level overhangs.

The market context is the bull case’s best card: HCM diagnosis is expanding, cardiologists are newly primed to treat it pharmacologically rather than surgically, and a class growing at 60% year over year has room for a credible third product. The bear case is that “room for a third product” is a share-fight assumption, not an open-market one — every Braveheart prescription will be won from an incumbent or from Cytokinetics’ launch, at marketing costs the incumbents are already amortizing.

Risks and What Could Go Wrong

1. Execution speed: the oHCM Phase 3 starting “later this year” and the nHCM trial in H1 2027 put first readouts in 2028-2029 — two to three years of burn against competitors who will have filed, launched, and expanded by then.
2. The Chinese Phase 2 doesn’t replicate: enrollment differences, standard-of-care backgrounds, and endpoint conduct frequently soften origin-trial results when run globally.
3. Hengrui friction: license terms, territory disputes, or the licensor’s own ambitions complicate the asset in ways a wholly-owned molecule never would.
4. Lockup and supply: post-IPO shares typically face a ~180-day lockup expiring well before any Phase 3 data — the classic window where early money exits and late money has no catalyst to buy against.

Position read: BRVE is a well-capitalized bet on class expansion with a weak timing position — third into oHCM, second into a contested nHCM race. The IPO price paid for execution that hasn’t happened; the honest sizing treats it as a Phase 3 option with two years of duration risk.